Prostate cancer usually causes no noticeable symptoms in its early stages, but various urinary problems appear once the ...

Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...

Prostate cancer is the second leading cause of cancer deaths among men in the U.S. with more than 35,000 dying in 2025. It’s ...

Breast and prostate cancer incidence is rising among people of every race and ethnicity in the U.S., while lung cancer incidence and death rates are ...

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to ...

Daiichi Sankyo and Merck announces ifinatamab deruxtecan BLA for certain patients with previously treated ES-SCLC voluntarily withdrawn: Rahway, New Jersey Monday, September 28, 2 ...

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the ...

Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab ...

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) ...

Merck & Co. Inc. MRK and healthcare company Daiichi Sankyo voluntarily pulled their U.S. Biologics License Application (BLA) ...

US FDA approves Welireg plus Lenvima for certain previously treated adult patients with advanced RCC with a clear cell component: Rahway, New Jersey Monday, September 28, 2026, 14 ...

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the ...